Tag: meeting

New York, NY, July 31, 2025 (GLOBE NEWSWIRE) -- The Ether Machine, the ether generation company, announced yesterday that The Ether Reserve LLC has purchased nearly 15,000 ETH at $3,809.97 USD for a total of $56,900,000.01 USD as part of The Ether Machine’s long-term accumulation strategy. This brings total ETH purchased and committed to 334,757 with up to $407,000,000 of USD remaining for additional ETH purchases.

Contact: Jessica Marshall                                 (778)716-6706

VANCOUVER, British Columbia, July 31, 2025 (GLOBE NEWSWIRE) -- Rubicon Organics Inc. (TSXV: ROMJ) (OTCQX: ROMJF) (“Rubicon Organics” or the “Company”), a licensed producer focused on cultivating and selling organic certified and premium cannabis, reports the voting results from its Annual General and Special Meeting of shareholders (the “Meeting”) held earlier today.

Reports Adjusted EBITDAS of $9.6 million, representing a 16% improvement from prior year

NORTHBOROUGH, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- Aspen Aerogels, Inc. (NYSE: ASPN) ("Aspen" or the "Company"), a technology leader in sustainability and electrification solutions, today announced that the Company is scheduled to participate in the following investor events in August: (i) Oppenheimer 28th Annual Technology, Internet & Communications Conference, and (ii) Canaccord Genuity 45th Annual Growth Conference. The presentation materials utilized during the conferences will be available on the Investor Relations section of Aspen's website at www.aerogel.com.

MONTREAL, July 31, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltda., has submitted a supplemental application to ANVISA, the Brazilian health regulatory agency, seeking approval for an additional indication for MINJUVI® (tafasitamab) in combination with rituximab and lenalidomide for the treatment of adult patients with previously treated follicular lymphoma (FL). The supplemental application for the additional indication was selected for review under Project Orbis.

HOUSTON, July 31, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced second quarter 2025 financial results and provided a corporate update.